Entrada Therapeutics Q2 net loss narrows to $42.8M; revenue falls to $0.9M
Entrada Therapeutics reported second quarter 2026 results, with a net loss of $42.8 million, slightly narrower than $43.1 million a year earlier. Collaboration revenue fell to $0.9 million from $2.0 million, and cash, cash equivalents and marketable securities dropped to $223.0 million from $295.7 million at December 31, 2025. The company said its cash is sufficient to fund operations into the third quarter of 2027 and listed several clinical data readouts expected between October 2026 and the first half of 2027.
Key points
- Net loss was $42.8 million, or $1.01 per share, versus $43.1 million, or $1.04 per share, in Q2 2025.
- Collaboration revenue was $0.9 million, down from $2.0 million in Q2 2025.
- Cash, cash equivalents and marketable securities were $223.0 million on June 30, 2026, versus $295.7 million on December 31, 2025; the company expects them to fund operations into Q3 2027.
- ELEVATE-45-201 Cohort 1 data are expected in October 2026, and ELEVATE-44-201 Cohort 1 open-label data by year-end 2026.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.